Mesirow Financial Investment Management Inc. Sells 3,706 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Mesirow Financial Investment Management Inc. reduced its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 23.1% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,318 shares of the company’s stock after selling 3,706 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Syndax Pharmaceuticals were worth $293,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Wellington Management Group LLP boosted its holdings in Syndax Pharmaceuticals by 2.7% during the 3rd quarter. Wellington Management Group LLP now owns 7,642,446 shares of the company’s stock valued at $110,968,000 after acquiring an additional 198,262 shares during the period. Kynam Capital Management LP lifted its stake in shares of Syndax Pharmaceuticals by 41.5% in the 4th quarter. Kynam Capital Management LP now owns 5,660,000 shares of the company’s stock valued at $122,313,000 after purchasing an additional 1,660,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Syndax Pharmaceuticals by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,335,353 shares of the company’s stock valued at $93,687,000 after purchasing an additional 718,051 shares during the period. Avoro Capital Advisors LLC lifted its stake in shares of Syndax Pharmaceuticals by 65.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,222,222 shares of the company’s stock valued at $91,242,000 after purchasing an additional 1,666,667 shares during the period. Finally, Avidity Partners Management LP increased its position in Syndax Pharmaceuticals by 40.0% during the 4th quarter. Avidity Partners Management LP now owns 3,950,000 shares of the company’s stock valued at $85,360,000 after buying an additional 1,129,000 shares in the last quarter.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, CFO Keith A. Goldan purchased 1,250 shares of the business’s stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $20.03 per share, with a total value of $25,037.50. Following the completion of the acquisition, the chief financial officer now owns 52,623 shares of the company’s stock, valued at approximately $1,054,038.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX traded down $0.58 during trading hours on Wednesday, hitting $20.08. The stock had a trading volume of 402,589 shares, compared to its average volume of 1,118,900. Syndax Pharmaceuticals, Inc. has a 12 month low of $11.22 and a 12 month high of $25.34. The stock has a fifty day moving average price of $20.50 and a 200 day moving average price of $21.54.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.11. During the same period in the prior year, the business posted ($0.59) earnings per share. As a group, sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.49 EPS for the current year.

Analysts Set New Price Targets

SNDX has been the subject of a number of analyst reports. Stifel Nicolaus raised their price objective on Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 26th. Jefferies Financial Group assumed coverage on Syndax Pharmaceuticals in a report on Friday, June 28th. They issued a “buy” rating and a $37.00 target price for the company. Scotiabank lowered Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, June 14th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $34.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, May 21st. Finally, Citigroup reduced their target price on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $34.77.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).